Comparison of effects of Rituximab and Cyclophosphamide combined with Prednisone acetate in treatment of refractory nephrotic syndrome in children
Objective:To compare effects of Rituximab and Cyclophosphamide combined with Prednisone acetate in treatment of refractory nephrotic syndrome(RNS)in children.Methods:A prospective study was conducted on 60 children with RNS admitted to this hospital from November 2021 to November 2022.According to the random number table method,they were divided into study group and control group,30 cases in each group.Both groups were treated with oral Prednisone acetate tablets.On this basis,the control group was treated with Cyclophosphamide for injection,while the study group was treated with Rituximab injection.The clinical efficacy,the renal function indexes[blood urea nitrogen(BUN),serum creatinine(Scr),24 h urinary protein quantification(24hUP)]levels,the blood lipid indexes[low-density lipoprotein cholesterol(LDL-C),triacylglycerol(TG),total cholesterol(TC)]levels before and after the treatment,and the incidence of adverse reactions and recurrence rate were compared between the two groups.Results:The total effective rate of the study group was 93.33%(28/30),which was higher than 73.33%(22/30)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of BUN,Scr,24hUP,LDL-C,TG and TC in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After 1 year of follow-up,the recurrence rate of the study group was 6.67%,which was lower than 26.67%of the control group,and the difference was statistically significant.Conclusions:Rituximab combined with Prednisone acetate is effective in the treatment of RNS in the children,which can improve the renal function and reduce the blood lipid levels and the recurrence rate.Moreover,it is superior to Cyclophosphamide combined with Prednisone acetate treatment.